Commentary on: Synthetic Reabsorbable Mesh (GalaFLEX) as Soft Tissues Adjunct in Breast Augmentation Revisional Surgery.

Abstract

Buccheri and colleagues present a well-performed retrospective review of 34 nonconsecutive patients who underwent revisional aesthetic breast surgery with GalaFLEX (Galatea Surgical; Lexington, MA).1 All patients had a previous breast augmentation in the submuscular plane, and revision included changing the implant to a subglandular plane with or without a mastopexy. In this study GalaFLEX was utilized on the anterior superomedial pole to cover the implant, with the main purpose being to improve soft tissue coverage of the implant and protect against capsular contracture. The main objectives of this study, both to improve soft tissue coverage of breast implants and to protect against capsular contracture, are unique endpoints and objectives for the use of GalaFLEX. Poly-4-hydroxybutyrate (P4HB) was approved by the FDA in 2007 as a resorbable high-strength suture. Following its approval, P4HB mesh devices were introduced for a variety of clinical uses.2 GalaFLEX was introduced in 2011 and is indicated for soft tissue support and to elevate and reinforce soft tissue. The scaffold allows for rapid vascularization, and as the mesh becomes fully integrated it resorbs. It has notably been studied and proven to provide lower pole stability and support of the breast, initially in mastopexy alone, followed by support for implant-based primary and revisional aesthetic breast surgery.3-6